Finance

Beta
Lists
TEVA:NYSE
Teva Pharmaceutical Indstris Lmtd..
$33.08
0.00%
(0.00) 1D
$33.03
-0.15% (-0.050)
Pre-market
Closed: Jun 2, 4:00:06 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TEVA...
Mkt. cap
38.43B
Avg. vol.
7.09M
Volume
12.62K
P/E ratio
24.73
52-wk high
$37.34
52-wk low
$14.99
EPS
$1.34
Beta
0.84
Shares outstanding
1.16B
No. of employees
32K
Mkt. cap
38.43B
Avg. vol.
7.09M
Volume
12.62K
P/E ratio
24.73
52-wk high
$37.34
52-wk low
$14.99
EPS
$1.34
Beta
0.84
Shares outstanding
1.16B
No. of employees
32K
News stories
From sources across the web
Profile
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients and, to a lesser extent, contract manufacturing services and an out-licensing platform. Teva's primary branded products include Austedo which is used for the treatment of chorea associated with Huntington's disease and tardive dyskinesia; and Ajovy, used for the preventive treatment of migraine in adults. Additional branded drugs sold by Teva include Copaxone, Bendeka and Treanda, all of which are primarily sold in the United States. Teva is listed on the Tel Aviv Stock Exchange and the New York Stock Exchange. Its manufacturing facilities are located in Israel, North America, Europe, Australia, and South America. The company is a member of the Pharmaceutical Research and Manufacturers of America. Teva Pharmaceuticals is the largest generic drug manufacturer in the world. Overall, Teva is the 26th largest pharmaceutical company in the world. Teva has a history of legal trouble in relation to collusion and price-fixing to inflate prices for drugs. Wikipedia
About Teva Pharmaceutical Indstris Lmtd..
CEORichard Francis
Employees32K
FoundedFeb 13, 1944
Headquarters-
SectorPharmaceutical industry
Websiteteva.co.il
Last report
Apr 29, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$0.53 / $0.46
+16.23%beat
Revenue / Est. (USD)
3.98B / 3.79B
+5.14%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
4.18B
4.48B
4.71B
3.98B
Cost of goods sold
2.07B
2.18B
2.06B
2.01B
Cost of revenue
2.07B
2.18B
2.06B
2.01B
Research and development expenses
244.00M
256.00M
267.00M
222.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
959.00M
973.00M
1.12B
1.00B
Operating expense
1.21B
1.24B
1.37B
1.21B
Total operating expenses
3.28B
3.41B
3.43B
3.22B
Operating income
894.00M
1.07B
1.28B
763.00M
Other non operating income
-90.00M
-27.00M
-
-13.00M
EBT including unusual items
204.00M
648.00M
90.00M
436.00M
EBT excluding unusual items
643.00M
832.00M
1.08B
547.00M
Income tax expense
-78.00M
214.00M
-390.00M
67.00M
Effective tax rate
-38.24%
33.02%
-433.33%
15.37%
Other operating expenses
5.00M
9.00M
-17.00M
-14.00M
Net income
282.00M
433.00M
480.00M
369.00M
Net profit margin
6.75%
9.67%
10.19%
9.27%
Earnings per share
0.66
0.78
0.96
0.53
Interest and investment income
-
-
92.00M
-
Interest expense
-220.00M
-205.00M
-280.00M
-191.00M
Net interest expenses
-220.00M
-205.00M
-188.00M
-191.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.14B
1.32B
1.54B
1.00B
Gain or loss from assets sale
-2.00M
-
-
-8.00M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer